<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00461136</url>
  </required_header>
  <id_info>
    <org_study_id>CSPP100A2242</org_study_id>
    <nct_id>NCT00461136</nct_id>
  </id_info>
  <brief_title>Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes</brief_title>
  <official_title>An Open-label, One-period, One-treatment Study to Evaluate the Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes Suffering From Incipient and/or Established Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the time-course of the antiproteinuric effect of renin inhibition
      with Aliskiren in patients with Type 2 diabetes suffering from incipient and/or established
      nephropathy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the time-course of the antiproteinuric effect of renin inhibition with Aliskiren in patients with Type 2 diabetes suffering from incipient and/or established nephropathy.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure blood pressure changes over time during the onset and offset of effect.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate whether there is a change on biomarkers of inflammation and cardiovascular risk.</measure>
  </secondary_outcome>
  <enrollment>18</enrollment>
  <condition>Diabetes Type 2</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and/or female patients from 30-80 years of age with a diagnosis of Type 2
             diabetes (WHO criteria).

          -  Incipient and established diabetic nephropathy (urinary albumin excretion ≥ 100 mg/day
             but ≤ 2000 mg/day).

          -  Glomerular filtration rate (GFR) ≥ 40 ml/min (estimated using Modification of Diet in
             Renal Disease (MDRD) formula) in the last 4 months.

          -  Female patients must be postmenopausal or must have had a bilateral oophorectomy or
             must have been surgically sterilized or hysterectomized at least 6 months prior to
             screening.

          -  To be eligible patients must fulfill the following criteria: Patients on ongoing
             hypertensive therapy must have a blood pressure ≥ 135/85 mm Hg but lower than 170/105
             mm Hg at baseline (Day -1) AND patients must be on stable antihypertensive medications
             for at least 8 weeks prior to baseline (Day -1).; Newly diagnosed hypertensive
             patients must have a blood pressure ≥ 135/85 mm Hg but lower than 170/105 mm Hg at
             baseline (Day -1).

          -  Patients must be on stable hypoglycemic medications for at least 8 weeks prior to
             Visit 2 ( Day -1).

          -  Patients must be willing and medically able to discontinue all Angiotensin-converting
             enzyme inhibitor (ACEI), Angiotensin receptor blocker (ARB), aldosterone receptor
             antagonist and potassium sparing diuretic medications for the duration of the study.

          -  Oral body temperature within the range 35.0-37.5 °C

          -  Able to provide written informed consent prior to study participation. .

          -  Able to communicate well with the investigator and comply with the requirements of the
             study.

        Exclusion Criteria:

          -  Severe Hypertension Grade 3 WHO classification (Mean Sitting Diastolic Blood Pressure
             (MSDBP) 110 mmHg and/or Mean Sitting Systolic Blood Pressure MSSBP 180 mmHg)

          -  Acetylsalicyclic acid (ASA) treatment &gt;1g/day or regular use of Non steroidal
             anti-inflammatory drug (NSAIDs)

          -  Kidney disease not caused by diabetes or hypertension

          -  Serum potassium &lt; 3.5 or &gt; 5.1 mEq/L

          -  GFR &lt; 40 ml/min/1.73m2 as measured by the MDRD formula

          -  Serum albumin &lt; 2.0mg/dL

          -  History of hypertensive encephalopathy or cerebrovascular accident at any time prior
             to Visit1.

          -  Current diagnosis of heart failure (New York Heart Association (NYHA) Class II-IV)

          -  History of myocardial infarction, unstable angina pectoris, coronary bypass surgery,
             or any percutaneous coronary intervention (PCI) during the 6 months prior to Visit 1

          -  Second or third degree heart block without a pacemaker

          -  Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia

          -  Clinically significant valvular heart disease

          -  Type 1 diabetes mellitus

          -  Uncontrolled Type II diabetes mellitus (Hemaglobin subtype A1C (HbA1C) &gt;11 %)

          -  History of malignancy including leukemia and lymphoma (but not basal cell skin
             carcinoma) within the past five years

          -  Participation in any clinical investigation within 4 weeks prior to dosing or longer
             if required by local regulation.

          -  Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing.

          -  Significant illness within the two weeks prior to dosing.

          -  Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism, or excretion of study drugs including, but not limited to,
             any of the following:

        History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or
        bowel resection

        -Currently active or previously active inflammatory bowel disease during the 12 months
        prior to Visit 1 Currently active gastritis, duodenal or gastric ulcers, or
        gastrointestinal/rectal bleeding during the 3 months prior to Visit 1.

        Any history of pancreatic injury, pancreatitis or evidence of impaired pancreatic
        function/injury as indicated by abnormal lipase or amylase Evidence of hepatic disease, a
        history of hepatic encephalopathy, a history of esophageal varices, or a history of
        portocaval shunt

          -  Current treatment with cholestyramine or cholestipol resins

          -  History of immunocompromise, including a positive HIV test result.

          -  History of a positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.

          -  History of drug or alcohol abuse within the 12 months prior to dosing.

          -  Persons directly involved in the execution of this protocol.

          -  Any condition that in the opinion of the investigator or the Novartis medical monitor
             would jeopardize the evaluation of efficacy or safety

          -  History of noncompliance to medical regimens or unwillingness to comply with the study
             protocol

          -  Known or suspected contraindications to the study medications, including history of
             allergy to Angiotensin converting enzyme (ACE) inhibitors and/or to thiazide diuretics
             or other sulfonamide derived drug

          -  Any surgical or medical condition, which in the opinion of the investigator, may place
             the patient at higher risk from his/her participation in the study, or is likely to
             prevent the patient from complying with the requirements of the study or completing
             the study

          -  Use of any prescription drug or over-the-counter (OTC) medication which is prohibited
             by the protocol.

          -  Patients who previously participated in any Aliskiren study.

          -  Pregnant or nursing woman.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigative site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2007</study_first_submitted>
  <study_first_submitted_qc>April 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2007</study_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <keyword>Time course</keyword>
  <keyword>antiproteinuric</keyword>
  <keyword>blood pressure</keyword>
  <keyword>lowering effect</keyword>
  <keyword>initiation of renin inhibition</keyword>
  <keyword>Aliskiren in Type 2 diabetes</keyword>
  <keyword>incipient and/or established nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

